Pharma channel feed

Ma­chine learn­ing, AI are chang­ing up how mar­keters think about ‘next best ac­tions’ to reach physi­cians

Last year
Marketing

Gilead re­news IT con­tract with Cog­nizant in bid to more quick­ly bring drugs to mar­ket 

Last year
Deals

Mar­ket­ingRx roundup: Sanofi teas­es #De­feat­Menin­gi­tis on so­cial; Mod­er­na launch­es mR­NA­Mon­day se­ries on Threads

Last year
Marketing

An­oth­er win for Novo's semaglu­tide? Physi­cians pre­fer it most in the emerg­ing field of NASH treat­ments, sur­vey finds

Last year
Marketing

Three take­aways and three burn­ing ques­tions for Chris Viehbacher's cost-cut­ting fu­ture at Bio­gen

Last year

Tar­sus scores first FDA ap­proval for treat­ment of red, itchy eyes caused by mites

Last year
FDA+

Hu­mani­gen warns of bank­rupt­cy af­ter fail­ing to bounce back from Covid-19 EUA re­jec­tion 

Last year
R&D

Ex­elix­is, Te­va reach set­tle­ment on Cabome­tyx patent dis­pute

Last year
Law

Te­va and Alvotech strike deal for 'in­creased in­volve­men­t' at Alvotech's trou­bled Ice­land site

Last year
Deals

Vi­iV's long-act­ing HIV in­jectable Cabe­nu­va pre­ferred over Bik­tarvy by 90% of pa­tients in PhI­II tri­al

Last year

Mer­ck evolves Keytru­da ad cam­paign, build­ing on pa­tient in­sights and high­light­ing 16 ap­provals

Last year
Marketing

FDA ap­proves Ver­ri­ca's skin in­fec­tion treat­ment, en­ters in­to non-bind­ing term sheet for $125M loan

Last year
FDA+

Phar­ma earn­ings sea­son starts with cor­po­rate prof­its, new CEOs tak­ing cen­ter stage

Last year

CHMP rec­om­mends against Mi­rati's KRAS ri­val, in fa­vor of Pfiz­er's RSV vac­cine, oth­er drugs

Last year
FDA+

Phar­ma brands dom­i­nate ‘new’ TV com­mer­cial list for first half of 2023, ad track­er re­ports

Last year
Marketing

Roche with­draws EMA ex­pan­sion ap­pli­ca­tion for can­cer med­i­cine Gazy­varo af­ter lack of 'ro­bust' tri­al meth­ods

Last year

Grail pushed a more re­stric­tive em­ploy­ee ar­bi­tra­tion agree­ment short­ly be­fore law­suits

Last year
Law

FTC cau­tions against re­ly­ing on its past PBM ad­vo­ca­cy as in­dus­try push­es back

Last year
FDA+

J&J plans to ap­peal $18.8M ver­dict in Cal­i­for­nia ba­by pow­der can­cer case

Last year

San­doz to in­vest $90M in Slove­nia site that will pro­duce biosim­i­lars

Last year

Pfiz­er set­tles trade se­crets case with com­pa­ny found­ed by ex-em­ploy­ees

Last year
Law

FDA re­ports short­age of No­vo Nordisk's weight loss drug Sax­en­da

Last year
Manufacturing

J&J down­sizes in­fec­tious dis­ease and vac­cine pipeline, cut­ting he­pati­tis B pro­grams

Last year
R&D

De­spite Dem op­po­si­tion, House com­mit­tee ad­vances pan­dem­ic pre­pared­ness bill sans drug short­age pro­vi­sions

Last year
FDA+
First page Previous page 113114115116117118119 Next page Last page
A service from the Financial Times